Nasdaq
$1.03▲ 2.49%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $158.9MShares out 1.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 8.28After-hours26.08.29 06:118-KKey event#●●●#●●●#●●●
Coherus Oncology, Inc.Bullish
On August 28, 2026, Coherus Oncology, Inc. entered into a sales agreement with Leerink Partners LLC to offer and sell up to $50 million of its common stock through an at-the-market offering. The company intends to use the net proceeds from these sales for general corporate purposes, including working capital.…more
$1.03+2.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.28After-hours26.08.29 05:34424B5Offering
Coherus Oncology, Inc.
Coherus Oncology has entered into a sales agreement with Leerink Partners to offer and sell up to $50 million of its common stock through an 'at-the-market' (ATM) offering. The net proceeds from this offering will be used for general corporate purposes, including research and development, commercial activities, and working capital.…more
$1.03+2.49%vs prev closeView filingShare - 8.28After-hours26.08.29 05:32424B3Offering
Coherus Oncology, Inc.
Coherus Oncology terminated its existing sales agreement (ATM program) with Cowen and Company, effective August 17, 2026. Consequently, the continuous offering and sale of up to $64,880,054 in common stock under the January 23, 2026, prospectus supplement have been terminated.…more
$1.03+2.49%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14After-hours26.10.15 05:30#●●●#●●●
Coherus Oncology to Present Interim Tagmokitug Clinical Data on October 28…more
Coherus Oncology announced it will host a webcast on October 28 to disclose interim clinical data for its solid tumor candidate, tagmokitug. The market will closely monitor the upcoming results to assess the potential efficacy and development progress of the drug.…more
$1.03+2.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.23Regular26.09.23 22:30
●●●●●●●● ●●●●● ●●●●●●
Coherus Oncology has retained Oppenheimer & Co. to manage the sale of its legacy biosimilar business assets. Proceeds from any potential transaction will be distributed to shareholders via Contingent Value Rights (CVRs).…more
$1.03+2.49%vs prev close - 8.31Regular26.08.31 22:30
●●●●●●●● ●●●●● ●●●●●●
Coherus Oncology announced its participation in several upcoming global healthcare investor conferences in September. Management will present the company's business strategy and pipeline progress during these events.…more
$1.03+2.49%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report